Background: Smokeless tobacco (SLT) use, particularly gutka and khaini, is a significant public health concern in India, mainly in rural areas. This prospective cohort study aimed to investigate the association between SLT use and oral cancer incidence among rural Indian men.
Methods: A cohort of 300 rural Indian men without a history of oral cancer was recruited and followed for five years. Baseline data on SLT use (type, frequency, and duration) and other risk factors were collected. Annual oral examinations and medical record reviews were conducted to identify incident cases of oral cancer. Incidence rates, relative risks, and hazard ratios (HR) were calculated to assess the association between SLT use and oral cancer.
Results: Among the 300 participants, 185 (61.7%) were SLT users at baseline. During follow-up, 25 incident cases of oral cancer were diagnosed. The incidence rate of oral cancer was significantly higher among SLT users (24.3 per 1,000 person-years) compared to non-users (5.4 per 1,000 person-years). After adjusting for confounders, the HR for oral cancer associated with SLT use was 4.51 (95% CI: 2.03-9.98), indicating a significantly increased risk. A dose-response relationship was observed, with higher frequency and longer duration of SLT use associated with increased risk.
Conclusions: This study provides strong evidence for a significant association between SLT use and increased risk of oral cancer among rural Indian men. The findings underscore the urgent need for targeted interventions to reduce SLT use and promote oral cancer awareness in this high-risk population.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11805294 | PMC |
http://dx.doi.org/10.4103/jpbs.jpbs_945_24 | DOI Listing |
Braz J Biol
March 2025
Centro Universitário CESMAC, Maceió, AL, Brasil.
Adenoid Cystic Carcinoma - ACC is a common neoplasm in major and minor salivary glands with a high risk of metastasis. Thus, the objective of the present study was to perform an analysis to better understand the histological grading systems of the ACC and its influence on tumor prognosis in terms of overall survival, disease-free and metastasis-free. This is a systematic review, with meta-analysis, based on the PRISMA parameters.
View Article and Find Full Text PDFJ Cancer Educ
March 2025
Département d´Odontologie, Faculté de Santé, Service d´Odontologie, Centre HospitalierUniversitaire, Université de Toulouse, 3 chemin des Maraîchers, Toulouse, 31400, France.
A patient who had undergone radiation therapy for cancer developed a white coating on their tongue. This was initially misdiagnosed as a fungal infection, leading to unnecessary treatment. The actual cause was dry mouth, a common side effect of radiation therapy.
View Article and Find Full Text PDFArch Dermatol Res
March 2025
Department of Dermatology, MD Anderson Cancer Center, Houston, TX, USA.
Aging Dis
February 2025
Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Nanozymes, which are nanomaterials that replicate the catalytic activities of natural enzymes in biological systems, have recently demonstrated considerable potential in improving cancer immunotherapy by altering the tumor microenvironment. Nanozyme-driven immune responses represent an innovative therapeutic modality with high effectiveness and minimal side effects. These nanozymes activate the immune system to specifically recognize and destroy cancer cells.
View Article and Find Full Text PDFInt J Cancer
March 2025
Center for Epigenetics & Disease Prevention, Texas A&M HEALTH, and Department of Translational Medical Sciences, Texas A&M University Naresh K. Vashisht College of Medicine, Houston, Texas, USA.
A previously reported clinical trial in familial adenomatous polyposis (FAP) patients treated with erlotinib plus sulindac (ERL + SUL) highlighted immune response/interferon-γ signaling as a key pathway. In this study, we combine intermittent low-dose ERL ± SUL treatment in the polyposis in rat colon (Pirc) model with mechanistic studies on tumor-associated immune modulation. At clinically relevant doses, short-term (16 weeks) and long-term (46 weeks) ERL ± SUL administration results in near-complete tumor suppression in Pirc colon and duodenum (p < 0.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!